SCHEMBL6628826

SCHEMBL6628826

COc1ccc2c(c1)OC1(C=C2)N(C)c2ccc(N3C(=O)CCC3=O)cc2C1(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.42
GAA P10253 6/20 0.42
LMNA P02545 6/20 0.42
KMT2A Q03164 5/20 0.42
SMN1; SMN2 Q16637 5/20 0.42
MEN1 O00255 4/20 0.42
RECQL P46063 3/20 0.42
TDP1 Q9NUW8 3/20 0.42
THRB P10828 3/20 0.42
PLIN1 O60240 1/20 0.42
PKM P14618 1/20 0.42
TSHR P16473 1/20 0.42
PLIN5 Q00G26 1/20 0.42
ABHD5 Q8WTS1 1/20 0.42
GFER P55789 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
ALPG P10696 1/20 0.40
TP53 P04637 1/20 0.40
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6630951 0.93 MAPT (0.50) MAPTGAALMNAKMT2ASMN1; SMN2
SCHEMBL6627625 0.85 MEN1 (0.36) MAPTGAALMNAKMT2ASMN1; SMN2
SCHEMBL6630398 0.82 MEN1 (0.45) MAPTGAALMNAKMT2ASMN1; SMN2
SCHEMBL6628794 0.82 MEN1 (0.49) MAPTGAALMNAKMT2ASMN1; SMN2
SCHEMBL6632591 0.81 MAPT (0.64) MAPTGAALMNAKMT2ASMN1; SMN2
SCHEMBL6629971 0.81 KMT2A (0.48) MAPTGAALMNAKMT2ASMN1; SMN2
SCHEMBL6629307 0.81 MEN1 (0.48) MAPTGAALMNAKMT2ASMN1; SMN2
SCHEMBL6628094 0.80 MAPT (0.39) MAPTGAALMNAKMT2ASMN1; SMN2
SCHEMBL8680159 0.80 MAPT (0.61) MAPTGAALMNAKMT2ASMN1; SMN2
SCHEMBL6630260 0.79 MEN1 (0.47) MAPTGAALMNAKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1299391-B1 INDOLINOSPIROPYRAN COMPOUNDS AND METHODS FOR THEIR MANUFACTURE JOHNSON & JOHNSON VISION CARE (US) 2004-12-29 EP disclosed
US-6803471-B2 USEFUL AS PHOTOCHROMIC COMPOUNDS; COVALENTLY ATTACHED TO WANG RESINS AND METHOD OF ATTACHING; OPHTHALMIC LENSES JOHNSON & JOHNSON VISION CARE, INC. 2004-10-12 US disclosed
US-6521753-B1 Indolinospiropyran compounds and methods for their manufacture JOHNSON & JOHNSON VISION CARE, INC. 2003-02-18 US disclosed
US-20020087010-A1 Indolinospiropyran compounds and methods for their manufacture ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) 2002-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020087010-A1 Indolinospiropyran compounds and methods for their manufacture DHPS, IDO1, INMT MAPT 537/4885GAA 3983/4885LMNA 2416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.